Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Samsung C&T attributed its first-quarter net profit surge of 55.8 percent to equity gains from its affiliate Samsung Biologics and profitable overseas projects.
The company, a construction affiliate of the Samsung Group, said in a regulatory filing that it had a net profit of 346.5 billion won for January to March, up from 222.4 billion won in the same period a year before.
Samsung C&T owns a 43.3 percent share in Samsung Biologics, a biopharmaceutical unit of Samsung Group.
The company claimed a first-quarter increase of 39.8 percent in its operating profit to 147 billion from 105 billion won in the same period last year.
However, Samsung C&T's revenue of 6.96 trillion won is a 5.4 percent dip from 7.35 trillion won last year. It attributed the drop to decreasing domestic consumption, and trading volume brought about by the COVID-19 situation, and for the completion of construction projects undertaken by the company.
Shares in Samsung C&T is up 3.3 percent to 97,000 won, outperforming KOSPI's gain of 0.89 percent gain.
"Increased equity gains from Samsung Biologics and profitable overseas projects boosted the first-quarter net profit," an official of Samsung C&T said.
